Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Published

Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal
Journal of psychiatry & neuroscience: JPN
Date
2013-03-01
Source
PubMed
DOI
10.1503/jpn.120128
PubMed
23171696

Authors

Young SN
Watch author

Derived topics and classifications

psilocybin DepressionAnxietyMechanism of ActionClinical TrialAnimal Study Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Research on Acute Toxicity and the Behavioral Effects of Methanolic Extract from Psilocybin Mushrooms and Psilocin in Mice2015-03-27Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.2013-03-01

Related papers

Editorial: Psychedelic substances and neurological diseases: from basics to clinical applicationFrontiers in Pharmacology · 2026-03-15Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.ClinicalTrials.gov · 2025-11-19Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain?UKnowledge (University of Kentucky) · 2025-03-04Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelicsFrontiers in Psychiatry · 2024-11-06Should addiction researchers be interested in psychedelic science?Drug and Alcohol Review · 2017-04-10